Internal link ProQR to Participate in 8th Annual Evercore Healthcare Conference décembre 01, 2025 at 01:00 PM UTC
Internal link ProQR Announces Third Quarter 2025 Operating and Financial Results novembre 06, 2025 at 12:00 PM UTC
Internal link ProQR Receives CTA Authorization for AX-0810 and Announces Virtual Investor and Analyst Event on November 3, 2025 octobre 20, 2025 at 12:00 PM UTC
Internal link ProQR to Participate in Upcoming Investor Conferences in October 2025 octobre 13, 2025 at 12:30 PM UTC
Internal link ProQR Announces Second Quarter 2025 Operating and Financial Results août 07, 2025 at 11:00 AM UTC
Internal link ProQR Announces Upcoming Presentation at RNA Editing Summit juillet 28, 2025 at 12:00 PM UTC
Internal link ProQR Announces CTA Submission for Phase 1 Study of AX-0810 Targeting NTCP juin 26, 2025 at 08:30 PM UTC
Internal link ProQR Announces Upcoming Scientific Presentations at ASGCT and TIDES Conferences mai 12, 2025 at 12:00 PM UTC
Internal link ProQR Announces First Quarter 2025 Operating and Financial Results mai 08, 2025 at 11:00 AM UTC
Internal link ProQR Announces Webcast of Presentation at the 2025 Citizens Life Sciences Conference mai 02, 2025 at 12:00 PM UTC
Internal link ProQR Announces Annual General Meeting of Shareholders to be Held June 3, 2025 mai 01, 2025 at 12:00 PM UTC
Internal link ProQR Strengthens Leadership with Appointments of CFO and CMO to Support Next Phase of Growth avril 14, 2025 at 11:00 AM UTC
Internal link ProQR Announces Year End 2024 Operating and Financial Results mars 13, 2025 at 11:00 AM UTC
Internal link ProQR Announces First Patient Dosed in Phase 1/2 Aurora Trial of QR-1123 for Autosomal Dominant Retinitis Pigmentosa décembre 11, 2019 at 12:00 PM UTC
Internal link ProQR Receives Orphan Drug Designation from FDA for QR-1123 for Autosomal Dominant Retinitis Pigmentosa novembre 21, 2019 at 12:00 PM UTC
Internal link ProQR Announces Recent Progress and Financial Results for the Third Quarter of 2019 novembre 06, 2019 at 12:00 PM UTC
Internal link ProQR Announces Closing of Underwritten Public Offering of Ordinary Shares with Full Exercise of Underwriters’ Option to Purchase Additional Shares octobre 18, 2019 at 12:20 PM UTC
Internal link ProQR Prices $50 Million Underwritten Public Offering of Ordinary Shares octobre 16, 2019 at 03:17 AM UTC
Internal link ProQR Announces Proposed Underwritten Public Offering of Ordinary Shares octobre 15, 2019 at 09:15 PM UTC
Internal link ProQR Receives Rare Pediatric Disease Designation from FDA for Sepofarsen for the Treatment of LCA10 octobre 15, 2019 at 08:08 PM UTC
Internal link ProQR annonce des premiers résultats positifs pour l'essai de phase 1/2 du sepofarsen chez des patients souffrant d'ACL10 octobre 11, 2019 at 10:02 AM UTC
Internal link ProQR Announces Positive Top-Line Results from the Phase 1/2 Study of Sepofarsen in LCA10 Patients octobre 10, 2019 at 10:00 AM UTC
Internal link ProQR to Present Top-Line Results from the Phase 1/2 Study of Sepofarsen in LCA10 Patients ahead of AAO octobre 07, 2019 at 11:00 AM UTC